|
|
Post by seanismorris on Nov 19, 2015 22:08:50 GMT -5
While this study was not in people who had diabetes, Kalyani said the research is a reminder, especially to doctors who treat patients with diabetes and prediabetes, to keep in mind that some patients may respond differently to different foods. The researchers are currently enrolling volunteers in Israel for a longer-term follow-up dietary intervention study focused on people with consistently high blood sugar levels who are at risk of developing diabetes. www.cbsnews.com/news/huge-differences-even-when-people-ate-the-same-foods/---------- Maybe not MannKind related (?) but diabetes and Israel catch my attention these days. I do hope MannKind has an interest in Israel, especially for diabetes studies/trials/TS etc. |
|
|
|
Post by rrtzmd on Nov 19, 2015 23:35:47 GMT -5
While this study was not in people who had diabetes, Kalyani said the research is a reminder, especially to doctors who treat patients with diabetes and prediabetes, to keep in mind that some patients may respond differently to different foods. The researchers are currently enrolling volunteers in Israel for a longer-term follow-up dietary intervention study focused on people with consistently high blood sugar levels who are at risk of developing diabetes. www.cbsnews.com/news/huge-differences-even-when-people-ate-the-same-foods/---------- Maybe not MannKind related (?) but diabetes and Israel catch my attention these days. I do hope MannKind has an interest in Israel, especially for diabetes studies/trials/TS etc. The full study is here: full text of paperI'm already put off by a number of things. The title "Personalized Nutrition by Prediction of Glycemic Responses" makes me wonder if this isn't a setup for some company offering "personalized nutrition." I have seen the Weizmann Institute involved in a number of very shady dealings with some publicly traded stocks and the IPO hair on my neck are standing up. Most of the authors are immunologists and the overall slant of the article seems to be one of modifying the "microbiome" to find an individual's "optimum." The gut microbiome and probiotics have been a relatively frequent topic in the popular science press the past year since the FDA banned fecal microbiota transplants, and I'm a bit suspicious as to why so much effort was put into this particular paper. There are also technical issues -- e.g. using a $30 Bayer Contour to calibrate the CGMs, while not wrong, isn't reassuring. I haven't had time to study any further. |
|
|
|
Post by seanismorris on Nov 20, 2015 1:13:57 GMT -5
I agree...mostly.
Every study should be considered suspect without knowing the authors motivation, but they don't seem to be pushing a specific product. I do see probiotic being the new vitamin as a revenue driver, and could be a billion dollar business (with possibly questionable value).
I do think there is something strange going on in human digestion in insulin production/resistance. Whether that's bacteria related, I don't know. I am very interested to see what comes out of increased availability of CGMs and data collection/analysis.
I didn't get into the authors pedigree, but if it was occurring with a university's participation that would be interesting. Al Mann has strong ties there...
|
|
|
|
Post by seanismorris on Nov 20, 2015 12:19:24 GMT -5
|
|
